Mounjaro Reduces Heart Attack and Stroke Risk by 33%: What 2026’s Cardiovascular Data Means for Americans
A 2026 study found tirzepatide (Mounjaro/Zepbound) reduces major cardiovascular events including heart attack and stroke by 33% in people with obesity and cardiovascular risk. A 40-year pharmacist explains the mechanisms, who benefits most, and what this means for Americans weighing GLP-1 treatment options.